CN114829399A - 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 - Google Patents

使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 Download PDF

Info

Publication number
CN114829399A
CN114829399A CN202080062829.8A CN202080062829A CN114829399A CN 114829399 A CN114829399 A CN 114829399A CN 202080062829 A CN202080062829 A CN 202080062829A CN 114829399 A CN114829399 A CN 114829399A
Authority
CN
China
Prior art keywords
cells
antigen
antibody
ser
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080062829.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·桑德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heimer Zhenke Pharmaceutical Co ltd
Original Assignee
Heimer Zhenke Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/506,764 external-priority patent/US11104738B2/en
Application filed by Heimer Zhenke Pharmaceutical Co ltd filed Critical Heimer Zhenke Pharmaceutical Co ltd
Publication of CN114829399A publication Critical patent/CN114829399A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080062829.8A 2019-07-09 2020-07-08 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法 Pending CN114829399A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/506764 2019-07-09
US16/506,764 US11104738B2 (en) 2016-04-04 2019-07-09 Monoclonal antibodies to human FLT3/FLK2 receptor protein
PCT/US2020/041095 WO2021007266A1 (fr) 2019-07-09 2020-07-08 Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques

Publications (1)

Publication Number Publication Date
CN114829399A true CN114829399A (zh) 2022-07-29

Family

ID=74115143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062829.8A Pending CN114829399A (zh) 2019-07-09 2020-07-08 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法

Country Status (5)

Country Link
EP (1) EP3997128A4 (fr)
JP (1) JP2022540602A (fr)
CN (1) CN114829399A (fr)
CA (1) CA3146912A1 (fr)
WO (1) WO2021007266A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016212162A1 (en) * 2015-01-26 2017-07-13 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to CD123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
EP3285792B1 (fr) * 2015-04-20 2020-11-04 The Board of Regents of The University of Texas System Clec11a en tant qu'agent de croissance osseuse
CA3019581A1 (fr) * 2016-04-04 2017-10-12 Hemogenyx Llc Procede d'elimination de cellules souches hematopoietique/progeniteurs hematopoietiques (csh/ph) chez un patient a l'aide d'anticorps bispecifiques
KR20230082055A (ko) * 2016-06-17 2023-06-08 마젠타 테라퓨틱스 인코포레이티드 세포의 고갈을 위한 조성물 및 방법
EP3612568B8 (fr) * 2017-04-18 2021-12-08 Autolus Limited Cellule

Also Published As

Publication number Publication date
CA3146912A1 (fr) 2021-01-14
WO2021007266A1 (fr) 2021-01-14
EP3997128A4 (fr) 2023-10-18
EP3997128A1 (fr) 2022-05-18
JP2022540602A (ja) 2022-09-16

Similar Documents

Publication Publication Date Title
JP7451627B2 (ja) キメラ受容体及びその使用方法
CN109562164B (zh) 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法
JP7479290B2 (ja) Ｄｌｌ３に対するキメラ受容体及びその使用方法
EP3105252B1 (fr) Anticorps bispécifiques utilisables dans une transplantation de cellules souches
JP2021118719A (ja) Ｔｉｇｉｔ結合物質およびその使用法
DK1648507T3 (en) PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
JP2019516352A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
JP2023036896A (ja) 二重特異性ｃｄ３３およびｃｄ３結合タンパク質を使用する方法
TW202045547A (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
WO2017023859A1 (fr) Protéines de liaison d'antigène ciblant cd56 et leurs utilisations
US20230048244A1 (en) Anti-tcr antibody molecules and uses thereof
US11104738B2 (en) Monoclonal antibodies to human FLT3/FLK2 receptor protein
TW202019464A (zh) 針對ｓｔｅａｐ１的嵌合受體及其使用方法
CN114829399A (zh) 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法
TWI842703B (zh) Dll3 的嵌合受體及其使用方法
EP4378953A1 (fr) Fraction de ciblage de cd29 pour le traitement du cancer positif de cd29
US20210363252A1 (en) Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
CA3229520A1 (fr) Anticorps bispecifiques anti-flt3/cd3 et leurs methodes d'utilisation
AU2022330106A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
WO2022214681A1 (fr) Méthodes de traitement d'un lymphome anaplasique à grandes cellules
JP2022518187A (ja) 抗体
EA044866B1 (ru) Химерные рецепторы к flt3 и способы их применения
MXPA06000841A (es) Metodos y composiciones para aumentar la eficiencia de anticuerpos terapeuticos que utilizan compuestos para potenciar celulas nk

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination